

# Synthesis of L-Sugars from 4-Deoxypentenosides


Fabien P. Boulineau and Alexander Wei\*

Department of Chemistry, Purdue University, 1393 Brown Building,  
West Lafayette, Indiana 47907-1393

alexwei@purdue.edu

Received May 11, 2002

## ABSTRACT



4-Deoxypentenosides, which are readily derived from D-sugars, resemble glycals in structure and reactivity and can undergo stereoselective epoxidation and  $S_N2$  nucleophilic addition to produce L-sugars in pyranosidic form.

L-Sugars, designated as such by the configuration of the stereogenic carbon most remote from the aldehyde/keto functionality,<sup>1</sup> have been a subject of enduring scientific interest. L-Sugars in their pyranosidic forms are important constituents of antibiotics<sup>2</sup> and clinically useful agents such as heparin;<sup>3</sup> they have also demonstrated potential as noncaloric sweeteners<sup>4</sup> and selectively toxic insecticides.<sup>5</sup> Numerous synthetic approaches toward L-pyranosides have been reported, including de novo syntheses,<sup>6</sup> homologation of shorter-chain sugars,<sup>7</sup> and epimerization of readily available D-sugars.<sup>8</sup> Most strategies involving the latter employ an acyclic intermediate to establish the C5 stereocenter, which often leads to a mixture of products upon cyclization.

(1) McNaught, A. D. *Pur. Appl. Chem.* **1996**, *68*, 1919–2008.  
(2) Collins, P. M. *Dictionary of Carbohydrates*; Chapman and Hall: London, 1987.

(3) *Heparin—Chemical and Biological Properties; Clinical Applications*; Lane, D. A., Lindahl, U., Eds.; Edward Arnold: London, 1989.

(4) (a) Shallenberger, R. S.; Acree, T. E.; Lee, C. Y. *Nature* **1969**, *221*, 555–56. (b) Levin, G. V. U.S. Patent 4,262,032, 1981.

(5) (a) Levin, G. V.; Zehner, L. R. U.S. Patent 5,166,193, 1992. (b) Anzeveno, P. B.; Green, F. R., III. In *Synthesis and Chemistry of Agrochemicals, VI*; Baker, D. R., Fenyves, J. G., Lahm, G. P., Selby, T. P., Stevenson, T. M., Eds.; ACS Symposium Series 800; American Chemical Society: Washington, DC, 2002; pp 262–76.

(6) Examples of de novo syntheses: (a) Ko, S. Y.; Lee, A. W. M.; Masamune, S.; Reed, L. A.; Sharpless, K. B.; Walker, F. J. *Science* **1983**, *220*, 949–51. (b) Bednarski, M.; Danishefsky, S. J. *Am. Chem. Soc.* **1986**, *108*, 7060–67. (c) Takeuchi, M.; Taniguchi, T.; Ogasawara, K. *Synthesis* **1999**, 341–46.

(7) Examples of homologation: (a) Sowden, J. C.; Fischer, H. O. *J. Am. Chem. Soc.* **1945**, *67*, 1713–15. (b) Kuhn, R.; Klesse, P. *Chem. Ber.* **1958**, *91*, 1989–91. (c) Dondoni, A.; Marra, A.; Massi, A. *J. Org. Chem.* **1997**, *62*, 6261–67. (d) Takahashi, S.; Kuzuhara, H. *J. Chem. Soc. Perk. Trans. I* **1997**, 607–12. (e) Lubineau, A.; Gavard, O.; Alais, J.; Bonnaffé, D. *Tetrahedron Lett.* **2000**, *41*, 307–11.

Several groups have reported epimerization of the critical stereocenter without opening the pyranose ring,<sup>9</sup> but overall, an efficient synthetic route to L-pyranosides has been lacking.


Here we introduce a direct and potentially general approach to L-pyranosides via 4-deoxypentenosides (4,5-unsaturated pentopyranosides). These unsaturated sugars bear a strong resemblance to glycals, a widely used intermediate in the synthesis of oligosaccharides<sup>10</sup> and a variety of natural products.<sup>11</sup> Indeed, the methodology reported herein suggests that 4-deoxypentenosides and glycals have similar reactivity profiles: both can be stereoselectively epoxidized by dimethyloxirane (DMDO) and can react with carbon nucleophiles with inversion of configuration. We demonstrate this with a stereoselective, two-step synthesis of L-altropyranoside derivatives bearing a diverse range of functional groups at C5.

(8) Examples of C5 epimerization: (a) Blanc-Muesser, M.; Defaye, J. *Synthesis* **1977**, 568–69. (b) Jacquinet, J.-C.; Petitou, M.; Duchaussoy, P.; Lederman, I.; Choay, J.; Torri, G.; Sinay, P. *Carbohydr. Res.* **1984**, *130*, 221–41. (c) Ojeda, R.; de Paz, J. L.; Martín-Lomas, M.; Lassaletta, J. M. *Synlett* **1999**, 8, 1316–18. (d) Takahashi, H.; Hitomi, Y.; Iwai, Y.; Ikegami, S. *J. Am. Chem. Soc.* **2000**, *122*, 2995–3000.

(9) (a) Pegram, J. J.; Anderson, C. B. *Carbohydr. Res.* **1988**, *184*, 276–78. (b) Rochepeau-Jobron, L.; Jacquinet, J.-C. *Carbohydr. Res.* **1997**, *303*, 395–406. (c) Bazin, H. G.; Wolff, M. W.; Linhardt, R. J. *J. Org. Chem.* **1999**, *64*, 144–52.

(10) (a) Halcomb, R. L.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1989**, *111*, 6661–66. (b) Seeberger, P. H.; Bilodeau, M. T.; Danishefsky, S. J. *Aldrichimica Acta* **1997**, *30*, 75–92.

(11) Selected examples: (a) Aicher, T. D.; Buszek, K. R.; Fang, F. G.; Forsyth, C. J.; Jung, S. H.; Kishi, Y.; Scola, P. M. *Tetrahedron Lett.* **1992**, *33*, 1549–52. (b) Hayward, M. M.; Roth, R. M.; Duffy, K. J.; Dalko, P. L.; Stevens, K. L.; Guo, J.; Kishi, Y. *Angew. Chem., Int. Ed.* **1998**, *37*, 192–96. (c) Evans, D. A.; Trotter, B. W.; Côté, B. *Tetrahedron Lett.* **1998**, *39*, 1709–12. (d) Rainier, J. D.; Allwein, S. P. *J. Org. Chem.* **1998**, *63*, 5310–11.

Scheme 1<sup>a</sup>

<sup>a</sup> Reaction conditions: (a) (i) TEMPO (5 mol %), KBr (10 mol %), *n*-Bu<sub>4</sub>NBr (5 mol %), NaOCl, NaHCO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O, 0 °C; (ii) *N,N*-dimethylformamide diisopentyl acetal (5 equiv), toluene, 120 °C (70% overall yield). (b) 0.1 M DMDO in acetone, CH<sub>2</sub>Cl<sub>2</sub>, -55 °C (quantitative yield).

4-Deoxypentenoside **1** was prepared from the corresponding methyl  $\alpha$ -D-glucoside in 70% yield by a two-step oxidation–decarboxylative elimination, modified from a procedure reported by Zemlicka and co-workers (see Scheme 1).<sup>12</sup> Several methods for epoxidation were investigated; however, the sensitivity of the resulting 4,5-epoxy-pyranosides to acidic hydrolysis precluded purification by silica chromatography, placing considerable limitations on the choice of reagents and reaction media (see Table 1 for selected

Table 1. Selected Epoxidation Conditions for 4-Deoxypentenoside **1**

condition <sup>a</sup>	$\beta$ : $\alpha$ selectivity
MMPP, NaHCO <sub>3</sub> , CH <sub>2</sub> Cl <sub>2</sub> , rt	NR
<i>m</i> -CPBA, NaHCO <sub>3</sub> , CH <sub>2</sub> Cl <sub>2</sub> /H <sub>2</sub> O, 0 °C	2:1
CF <sub>3</sub> C(O)Me/trifluoroacetone, CH <sub>2</sub> Cl <sub>2</sub> , -78 °C	5:1
DMDO/acetone, CH <sub>2</sub> Cl <sub>2</sub> , -20 °C (4 h)	5:1
DMDO/acetone, CH <sub>2</sub> Cl <sub>2</sub> , -55 °C (48 h)	10:1


<sup>a</sup> MMPP = magnesium monoperoxyphthalate; *m*-CPBA = *m*-chloroperoxybenzoic acid; DMDO = 2,2-dimethyldioxirane.

conditions). Nevertheless, we observed that epoxidation of **1** with DMDO at -55 °C proceeded quantitatively with  $\beta$ : $\alpha$  selectivities of approximately 10:1, as determined by <sup>1</sup>H NMR spectroscopy (300 MHz, C<sub>6</sub>D<sub>6</sub>) and the ensuing product ratios (see below). Epoxidation stereoselectivity was strongly affected by the transannular substituents, which can influence both the pentenoside ring conformation and the local steric environment; for example, epimerization at C1 or C2 resulted in high selectivity for the  $\alpha$  face (see Table 2).<sup>13</sup>

Table 2. Substituent Effects on 4-Deoxypentenoside Epoxidation

configuration	$\beta$ : $\alpha$ selectivity
$\alpha$ -methyl gluco ( <b>1</b> )	10:1 <sup>a</sup>
$\alpha$ -isopropyl gluco	8:1 <sup>a</sup>
$\beta$ -isopropyl gluco	1:5 <sup>b</sup>
$\alpha$ -methyl manno	>1:20 <sup>b</sup>

<sup>a</sup> DMDO (0.1 M) in acetone/CH<sub>2</sub>Cl<sub>2</sub>, -55 °C. <sup>b</sup> DMDO (0.1 M) in acetone/CH<sub>2</sub>Cl<sub>2</sub>, 0 °C.


Table 3. Nucleophilic Ring-Opening of  $\beta$ -Epoxide **2**

entry	nucleophile	react cond	product	yield
a	<sup>13</sup> CH <sub>3</sub> MgI	A		57% <sup>b</sup>
b		B		78% <sup>c</sup>
c		B		70% <sup>b</sup>
d		B		52% <sup>b</sup>
e	PhMe <sub>2</sub> Si-CH <sub>2</sub> MgCl	B		86% <sup>b</sup>
f		A		69% <sup>c</sup>
g	KCN	C		68% <sup>b</sup>
h	NaN <sub>3</sub>	C		77% <sup>b</sup>
i	4-MePhSLi	D		72% <sup>c</sup>
j	LiAlD <sub>4</sub>	E		69% <sup>c</sup>

<sup>a</sup> Reaction conditions: (A) 3.5 equiv of Nu, 1.5 equiv of CuI, THF, -10 °C. (B) 3.5 equiv of Nu, 0.1 equiv of CuI, THF, -10 °C. (C) 10–20 equiv of Nu in aq DMF, rt. (D) 9.0 equiv of Nu in THF, 0 °C. (E) 5.0 equiv of Nu in Et<sub>2</sub>O, rt. <sup>b</sup> Mixture of diastereomers = 10:1 L-altrio/D-gluco. <sup>c</sup> Isolated yield.

Epoxyglycoside **2** was evaluated for its reactivity under  $S_N2$  conditions with a broad set of nucleophiles.  $\beta$ -Epoxide ring-opening was observed to proceed in many cases with complete regioselectivity and inversion of stereochemistry at C5, producing the corresponding L-altro derivatives as the major products (see Table 3).<sup>14,15</sup> In particular, Cu(I)-assisted Grignard additions proceeded with both high yields and stereocontrol.<sup>16</sup> Similar nucleophiles have been reported to react with  $\alpha$ -epoxyglycals and related intermediates with inversion of configuration at C1.<sup>11b-d,17</sup> Heteroatomic nucleophiles were also observed to add in an  $S_N2$  fashion, yielding novel 1,5-bisacetals. It should be noted that several of the products in Table 3 can be readily converted to genuine L-hexopyranosides; for example, a Tamao–Fleming oxidation<sup>18</sup> on dimethylphenylsilane **3e** yields L-altropyranoside **4** in 75% yield (see Scheme 2).

The 4-deoxypentenose route toward L-sugars offers some distinct advantages over other synthetic methods: (i) it can



be used to install both natural and unnatural substituents at C5; (ii) it is an efficient method for introducing isotopic labels and can be used to prepare 6-<sup>13</sup>C-hexopyranosides;<sup>19</sup> and (iii) it provides direct access to protected L-pyranosides with fixed anomeric configurations and may be adapted directly toward the construction of 1,4-linked saccharides such as the glycosaminoglycans. We anticipate that 4-deoxypentenosides will also be useful as synthetic intermediates toward higher-order or exotic sugars and other complex tetrahydropyrans.<sup>11</sup>

**Acknowledgment.** The authors gratefully acknowledge support from the American Cancer Society (IRG-58-006-41), the American Chemical Society Petroleum Research Fund (36069-AC1), and the American Heart Association Midwest Affiliates (30399Z).

**Supporting Information Available:** Experimental procedures for the synthesis of compounds **1–4**, plus selected <sup>1</sup>H and <sup>13</sup>C NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL026175Q

(19) King-Morris, M. J.; Bondo, P. B.; Mrowca, R. A.; Serianni, A. S. *Carbohydr. Res.* **1988**, *175*, 49–58.

(12) Philips, K. D.; Zemlicka, J.; Horwitz, J. P. *Carbohydr. Res.* **1973**, *30*, 281–86.

(13) Transannular stereoelectronic effects on reactions involving tetrahydropyran ring systems have been noted previously: Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2000**, *122*, 168–69 and references therein.

(14) The product of entry **i** is formally a 5S-[<sup>2</sup>H]-L-arabinoside. It should be mentioned that additions to the minor  $\alpha$ -epoxide isomer also proceeded with inversion at C5 to yield the corresponding D-gluco derivatives.

(15) Stereochemistry was assigned on the basis of <sup>1</sup>H NMR coupling constants of both the major and minor stereoisomers, supplemented by nuclear Overhauser effect experiments (see Supporting Information).

(16) Erdik, E. *Tetrahedron* **1984**, *40*, 641–57. We have observed that Grignard additions without Cu(I) did not add exclusively by the  $S_N2$  pathway.

(17) (a) Bellosta, V.; Czernecki, S. *J. Chem. Soc., Chem. Commun.* **1989**, 199–200. (b) Bellosta, V.; Czernecki, S. *Carbohydr. Res.* **1993**, *244*, 275–84. (c) Best, W. M.; Ferro, V.; Harle, J.; Stick, R. V.; Tilbrook, D. M. G. *Aust. J. Chem.* **1997**, *50*, 463–72. (d) Chiappe, C.; Crotti, P.; Menichetti, E.; Pineschi, M. *Tetrahedron: Asymmetry* **1998**, *9*, 4079–88.

(18) Fleming, I.; Sanderson, P. E. J. *Tetrahedron Lett.* **1987**, *28*, 4229–32.